Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
In women with polycystic ovary syndrome, C-reactive protein levels and D-dimer, antithrombin III, activated protein C resistance, and activated partial thromboplastin time were unaffected by metformin treatment throughout pregnancy. Protein C levels increased slightly in the metformin group compared with the placebo group.
Vanky
Eszter
E
Department of Obstetrics and Gynaecology, Norwegian University of Science and Technology, Trondheim, Norway. eszter.vanky@medisin.ntnu.no
Salvesen
Kjell Asmund
KA
Hjorth-Hansen
Henrik
H
Bjerve
Kristian
K
Carlsen
Sven Magnus
SM
D020016:Activated Protein C Resistance / Q000453:epidemiology; D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects*; D002097:C-Reactive Protein / Q000378:metabolism*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D015994:Incidence; D008687:Metformin / Q000627:therapeutic use*; D010314:Partial Thromboplastin Time; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000188:drug therapy; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood* / Q000188:drug therapy; D011256:Pregnancy Outcome
D005338:Fibrin Fibrinogen Degradation Products; D007004:Hypoglycemic Agents; D000990:Antithrombin III; D002097:C-Reactive Protein; D008687:Metformin